Accepted Articles
Back to the articles list |
Back to browse issues page
Samira Kazemi1 
, Narges Hesni Langroudi1 , Peyman Hasani Abharian2 , Kamran Tavakol3 , Mohammad Taghi Joghtaei4 , Shima Tavakol * 4, Sepideh Arbabi Bidgoli1
, Narges Hesni Langroudi1 , Peyman Hasani Abharian2 , Kamran Tavakol3 , Mohammad Taghi Joghtaei4 , Shima Tavakol * 4, Sepideh Arbabi Bidgoli1
1- Faculty of Pharmacy and Pharmaceutical Sciences, Islamic Azad University, Tehran, Iran.
2- Brain and Cognition Clinic, Tehran, Iran.
3- College of Medicine, Howard University, Washington DC, USA.
4- Iran University of Medical Sciences, Tehran, Iran.
2- Brain and Cognition Clinic, Tehran, Iran.
3- College of Medicine, Howard University, Washington DC, USA.
4- Iran University of Medical Sciences, Tehran, Iran.
Abstract:
Alzheimer's disease (AD) is a progressive neurodegenerative disease accompanied by cognitive dysfunction. Preclinical changes can precede the onset of clinical symptoms by a decade, highlighting the need for preventative and therapeutic strategies to mitigate or delay disease progression This pilot clinical trial, for the first time, investigated the effects of commercially available curcumin nanomicelles on oxidative stress pathways and serum cholinesterase levels in patients with AD. Fifteen volunteers with mild to severe AD and fifteen age-matched healthy controls were enrolled. Participants with AD received 80 mg of thermodynamically stable 10 nm curcumin nanomicelles on alternate days for two months. cognitive function, as assessed by the Mini-Mental State Examination (MMSE) , did not exhibit significant changes in AD patients following curcumin nanomicelle administration (19.8 versus 20.6). Serum levels of oxidative stress biomarkers, including catalase, superoxide dismutase (SOD) inhibition, malondialdehyde (MDA) concentration, and cholinesterase activity, were evaluated before and after intervention. The results showed no significant differences between the cognition improvement, catalase activity, SOD inhibition, MOD concentration, and cholinesterase activity between AD patients and healthy controls, or before and after curcumin nanomicelle administration. It might be concluded that although curcumin nanocarriers did not enhance antioxidant biomolecules, they did not provoke lipid peroxidation mechanisms. Therefore, the study suggests that optimization of nanocarrier parameters, including concentration, particle size larger than 10 nm, and blood-brain barrier targeting, warrants further investigation in a long-term study to explore their potential as a supplemental therapy for AD.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
